Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

作     者：Nick Andrews 

作者机构：From the United Kingdom Health Security Agency (N.A. E.T. J.S. C.G. F.K. R.S. E.G. S.T. N.G. G.D. R.M. C.N.J.C. G.A. M.E. M.Z. K.B. S.H. M.C. S.N.L. M.R. J.L.B.) the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation London School of Hygiene and Tropical Medicine (N.A. C.N.J.C. G.A. K.B. M.R. J.L.B.) the NIHR Health Protection Research Unit in Respiratory Infections Imperial College London (M.Z. J.L.B.) Guy's and St. Thomas' Hospital NHS Trust (M.C.) and the Paediatric Infectious Diseases Research Group St. George's University of London (S.N.L.) London and Healthcare Associated Infections and Antimicrobial Resistance University of Oxford Oxford (S.H.) - all in the United Kingdom. 

出 版 物：《四川生理科学杂志》 (Sichuan Journal of Physiological Sciences)

年 卷 期：2021年第43卷第11期

页      面：1935-1935页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 100705[医学-微生物与生化药学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100103[医学-病原生物学] 10[医学] 

主　　题：Vaccine death. acute 

摘      要：Background:Vaccines against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the virus that causes coronavirus disease 2019(Covid-19),have been used since December 2020 in the United ***-world data have shown the vaccines to be highly effective against Covid-19 and related severe disease and *** effectiveness may wane over time since the receipt of the second dose of the ChAdOx1-S(ChAdOx1 nCoV-19)and BNT162b2 vaccines.